143 related articles for article (PubMed ID: 304143)
21. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications of hemoglobin levels before and after surgery as well as before and after radiochemotherapy for head and neck tumors.
Reichel O; Panzer M; Wimmer C; Dühmke E; Kastenbauer E; Suckfüll M
Eur Arch Otorhinolaryngol; 2003 May; 260(5):248-53. PubMed ID: 12750913
[TBL] [Abstract][Full Text] [Related]
23. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer.
Nguyen NP; Vos P; Lee H; Borok TL; Karlsson U; Martinez T; Welsh J; Cohen D; Hamilton R; Nguyen N; Nguyen LM; Vinh-Hung V
Oncology; 2008; 75(3-4):186-91. PubMed ID: 18841033
[TBL] [Abstract][Full Text] [Related]
24. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
[TBL] [Abstract][Full Text] [Related]
25. [Immunotherapy for head and neck squamous cell carcinoma].
Bron L; Romero P
Rev Med Suisse; 2006 Oct; 2(81):2216-9. PubMed ID: 17076151
[TBL] [Abstract][Full Text] [Related]
26. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
27. SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck.
Eibling DE; Johnson JT; Wagner RL; Su S
Laryngoscope; 1989 Feb; 99(2):117-24. PubMed ID: 2913421
[TBL] [Abstract][Full Text] [Related]
28. Immunobiologic aspects of head and neck cancer. Clinical and laboratory correlates.
Vlock DR
Hematol Oncol Clin North Am; 1991 Aug; 5(4):797-820. PubMed ID: 1716250
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of poor CD3 response in head and neck cancer.
Shibuya TY; Nugyen N; McLaren CE; Li KT; Wei WZ; Kim S; Yoo GH; Rogowski A; Ensley J; Sakr W
Clin Cancer Res; 2002 Mar; 8(3):745-51. PubMed ID: 11895904
[TBL] [Abstract][Full Text] [Related]
30. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
31. [Effects of transfer factor on the number of circulating lymphocytes in patients with spinocellular carcinoma of the cervicofacial area].
Mastromatteo V; Negri L; Pacchioni D; Calabrese F; Giacomasso S; Fazio M
Boll Soc Ital Biol Sper; 1987 Nov; 63(11):1043-50. PubMed ID: 3454189
[No Abstract] [Full Text] [Related]
32. Blood transfusions and phenotypic immune profile in head and neck cancer patients undergoing surgical resection.
MacRae JD; Lampe H; Banerjee D
J Otolaryngol; 1991 Oct; 20(5):310-4. PubMed ID: 1960784
[TBL] [Abstract][Full Text] [Related]
33. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
34. Immunological status of patients in carcinoma head and neck.
Vasenwala SM; Aziz M; Rattan A; Ahmad KN
Indian J Cancer; 1989 Sep; 26(3):137-44. PubMed ID: 2630426
[TBL] [Abstract][Full Text] [Related]
35. Decreased sensitivity of T lymphocytes to normal adherent suppressor cells in patients with head and neck cancer.
Pierri I; Cordone G; Rogna S; Pende D; Garaventa G; Barabino A; Indiveri F
Cancer Detect Prev; 1984; 7(2):73-8. PubMed ID: 6231991
[TBL] [Abstract][Full Text] [Related]
36. Tissue-cultured head and neck tumors: their use in in vitro assays of immune response.
Aust JC; Rabuzzi D; Reed G
Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol; 1977; 84(3 Pt 2):ORL602-8. PubMed ID: 196378
[TBL] [Abstract][Full Text] [Related]
37. Concomitant immunopathology with squamous cell carcinomas of the head and neck regions.
Berlinger NT; Good RA
Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol; 1976; 82(5):588-94. PubMed ID: 138999
[No Abstract] [Full Text] [Related]
38. Immunology of head and neck cancers.
Newbill ET; Johns ME
Crit Rev Clin Lab Sci; 1983; 19(1):1-25. PubMed ID: 6201320
[TBL] [Abstract][Full Text] [Related]
39. Deficient cell-mediated immunity in head and neck cancer patients secondary to autologous suppressive immune cells.
Berlinger NT; Hilal EY; Oettgen HF; Good RA
Laryngoscope; 1978 Mar; 88(3):470-83. PubMed ID: 146766
[TBL] [Abstract][Full Text] [Related]
40. Serial studies of immunocompetence in head and neck cancer patients undergoing radiation therapy.
Stefano S; Kerman R; Abbate J
AJR Am J Roentgenol; 1976 Apr; 126(4):880-6. PubMed ID: 179361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
